摘要 |
The invention relates to novel keto lactam compounds, hydrogenated derivatives and tautomers thereof. These compounds have valuable therapeutic properties and are particularly suited for treating diseases that respond to the modulation of the dopamine D<SUB>3 </SUB>receptor. The keto lactams have general formula (I), wherein: (a) represents a group of formulas (b) or (c), wherein D is bound to the nitrogen atom and W, R<SUP>p </SUP>and R<SUP>q </SUP>have the meanings cited in Claim 1 ; -B- represents a bond or (d), wherein R<SUP>m </SUP>and R<SUP>n </SUP>have the meanings cited in Claim 1; (e) represents a single bond or a double bond; R<SUP>v</SUP>, R<SUP>w</SUP>, R<SUP>x </SUP>and R<SUP>y </SUP>have the meanings cited in Claim 1; D represents a linear or branched 2 to 10-membered alkylene chain that can have, as chain members, a heteroatom group K, which is selected among O, S, S(O), S(O)<SUB>2</SUB>, N-R<SUP>8</SUP>, CO-O, C(O)NR<SUP>8 </SUP>and/or 1 or 2 non-adjacent carbonyl groups and which can have a cycloalkane diyl group and/or a double or triple bond: (f) represents a saturated or monounsaturated monocyclic nitrogen heterocyclic compound having 5 to 8 cyclic members or a bicyclic saturated nitrogens heterocyclic compound having 7 to 12 cyclic members.
|